Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Short term Debt (2016 - 2025)

Historic Short term Debt for Abeona Therapeutics (ABEO) over the last 11 years, with Q3 2025 value amounting to $8.9 million.

  • Abeona Therapeutics' Short term Debt rose 10002.25% to $8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.9 million, marking a year-over-year increase of 10002.25%. This contributed to the annual value of $5.9 million for FY2024, which is N/A changed from last year.
  • Per Abeona Therapeutics' latest filing, its Short term Debt stood at $8.9 million for Q3 2025, which was up 10002.25% from $5.6 million recorded in Q2 2025.
  • Abeona Therapeutics' 5-year Short term Debt high stood at $34.4 million for Q2 2021, and its period low was $2.2 million during Q2 2024.
  • Its 4-year average for Short term Debt is $10.9 million, with a median of $5.6 million in 2025.
  • Per our database at Business Quant, Abeona Therapeutics' Short term Debt plummeted by 8600.8% in 2022 and then surged by 15004.5% in 2025.
  • Abeona Therapeutics' Short term Debt (Quarter) stood at $4.6 million in 2021, then grew by 7.0% to $4.9 million in 2022, then grew by 20.42% to $5.9 million in 2024, then skyrocketed by 50.0% to $8.9 million in 2025.
  • Its last three reported values are $8.9 million in Q3 2025, $5.6 million for Q2 2025, and $8.1 million during Q1 2025.